METHORIVAC - Vaccinal Pharmacoepidemiologic
NCT01931813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2013-08-29
Summary
This project is the pilot step necessary to develop a system of vaccination pharmacoepidemiology that associates a sophisticated analytical approach, appropriate for this challenge and case series analysis, with the use of linked medicoadministrative data for hospitalisations the reimbursement of healthcare costs. This linkage of medicoadministrative data is new in France. The example of the risk of hospitalisation for febrile convulsions in infants less than two years old following vaccination against diphtheria, tetanus and pertussis is given as the reference association. This choice is justified by the numerous publications over many years on the existence of this association (Miller et al BMJ 1981, Farrington et al Lancet 1995). In addition, as case series analyses have been carried out to assess this risk, the results can be compared directly (Lancet 1995). The study to determine whether the analysis tools are suitable for the data will be tackled at the following levels:
* Validity of the selection of cases from administrative records alone using coding based on the international classification of diseases ICD10
* Validity of the risk assessment. This methodology feasibility project must make it possible to identify the different potential problems. This is a prerequisite necessary for the systematic implementation.
Conditions
- Infants Likely to Present Febrile Convulsions
Sponsors & Collaborators
-
Centre Hospitalier Universitaire Dijon
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2012-09-30
Countries
- France
Study Locations
More Related Trials
-
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
NCT00287092 ·Status: COMPLETED ·Phase: PHASE3
-
Pentavalent DTaP-Hep B-IPV
NCT00133445 ·Status: COMPLETED ·Phase: PHASE2
-
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
NCT01129362 ·Status: COMPLETED
-
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
NCT01839188 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)
NCT00551915 ·Status: COMPLETED ·Phase: PHASE2
-
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
NCT00831311 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
NCT04535037 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
NCT01480258 ·Status: COMPLETED ·Phase: PHASE3
-
To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants
NCT00420745 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
NCT00352963 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
NCT06618196 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico
NCT00436358 ·Status: COMPLETED
-
A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants
NCT01896739 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines
NCT05193734 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
NCT00463437 ·Status: COMPLETED ·Phase: PHASE3
-
Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants
NCT00586612 ·Status: COMPLETED ·Phase: PHASE3
-
Maternal Determinants of Infant Immunity to Pertussis
NCT05856396 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®
NCT00355654 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of a Tdap-IPV (Tetanus, Diphteria, Pertussis and Inactivated Polio) Vaccination Remedial Strategy on Vaccination Coverage in Patients 65 Years of Age or Older
NCT03587610 ·Status: UNKNOWN ·Phase: NA
-
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
NCT00343421 ·Status: COMPLETED ·Phase: PHASE3
-
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants
NCT01204658 ·Status: COMPLETED ·Phase: PHASE2
-
Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea
NCT01568060 ·Status: COMPLETED
-
Surveillance of Rotavirus Gastroenteritis
NCT02900703 ·Status: UNKNOWN
-
Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine
NCT00289796 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
NCT00317109 ·Status: COMPLETED ·Phase: PHASE3